

Naveni[®] PD1/PD-L1


BRINGING PRECISION TO SPATIAL PROTEOMICS

Detect PD1/PD-L1 interactions *in situ*


Despite the recent success of immune checkpoint inhibitors, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed¹. PD-L1 IHC is commonly used as a biomarker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear². Navinci has now developed the first commercial Proximity Ligation Assay for the specific detection of PD1/PD-L1 interactions *in situ*.

Naveni[®] PD1/PD-L1 enables you to:


- Detect the specific interaction of PD1/PD-L1 using dual recognition
- Identify interactions of low abundant PD1/PD-L1
- Visualize PD1/PD-L1 in the tissue micro-environment
- Increase understanding of PD1/PD-L1 signaling pathways
- Elucidate the potential of PD1/PD-L1 interaction as a predictive biomarker



The Naveni® PPI PD1/PD-L1 kit is based on our proprietary Naveni® Proximity Ligation Technology³. The kit includes two Navenibodies conjugated to proprietary oligo arms (depicted as orange antibodies in the illustration to the left). Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct signal.



PD1/PD-L1 interaction in the pancreatic ductal carcinoma, AP substrate



PD1/PD-L1 interaction in tonsil tissue, HRP substrate

Ordering information

Naveni PPI	Code	Read out	Primary antibodies required
Naveni PD1/PD-L1 HRP	PPI.PDL1.HRP.100	Brightfield	Primary included
Naveni PD1/PD-L1 AP	PPI.PDL1.AP.100	Brightfield and fluorescence	Primary included
Naveni PD1/PD-L1 Atto647N	PPI.PDL1.FR.100	Fluorescence	Primary included
Naveni PTM	Code	Read out	Primary antibodies required
Naveni pY PD1 AP	NPT.PD1.AP.100	Brightfield and fluorescence	Primary included
Naveni pY PD1 HRP	NPT.PD1.HRP.100	Brightfield	Primary included

Kit size: 4ml working solution.
For research use only. Not for use in diagnostic procedures.

1. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. *Nat Commun* 11, 3801 (2020).
2. Sánchez-Magràner L, et al., High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. *Cancer Res* 80, 19 (2020).
3. Klaesson A, et al., Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes. *Sci Rep.* 8(1):5400 (2018).



For product-specific images on different tissues and more info, visit our web.
Email: contact@navinci.se